Your browser doesn't support javascript.
loading
Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men.
Durussel, Jérôme; Daskalaki, Evangelia; Anderson, Martin; Chatterji, Tushar; Wondimu, Diresibachew H; Padmanabhan, Neal; Patel, Rajan K; McClure, John D; Pitsiladis, Yannis P.
Afiliación
  • Durussel J; Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
PLoS One ; 8(2): e56151, 2013.
Article en En | MEDLINE | ID: mdl-23418527
ABSTRACT
UNLABELLED Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb(mass)) and maximal oxygen uptake (v O(2 max)).

PURPOSE:

This study defined the time course of changes in Hb(mass), v O(2 max) as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field.

METHODS:

19 trained men received rHuEpo injections of 50 IU•kg(-1) body mass every two days for 4 weeks. Hb(mass) was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. v O(2 max) and 3,000 m time trial performance were measured pre, post administration and at the end of the study.

RESULTS:

Relative to baseline, running performance significantly improved by ∼6% after administration (1030±107 minsec vs. 1108±115 minsec, p<0.001) and remained significantly enhanced by ∼3% 4 weeks after administration (1046±113 minsec, p<0.001), while v O(2 max) was also significantly increased post administration (60.7±5.8 mL•min(-1)•kg(-1) vs. 56.0±6.2 mL•min(-1)•kg(-1), p<0.001) and remained significantly increased 4 weeks after rHuEpo (58.0±5.6 mL•min(-1)•kg(-1), p = 0.021). Hb(mass) was significantly increased at the end of administration compared to baseline (15.2±1.5 g•kg(-1) vs. 12.7±1.2 g•kg(-1), p<0.001). The rate of decrease in Hb(mass) toward baseline values post rHuEpo was similar to that of the increase during administration (-0.53 g•kg(-1)•wk(-1), 95% confidence interval (CI) (-0.68, -0.38) vs. 0.54 g•kg(-1•)wk(-1), CI (0.46, 0.63)) but Hb(mass) was still significantly elevated 4 weeks after administration compared to baseline (13.7±1.1 g•kg(-1), p<0.001).

CONCLUSION:

Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated v O(2 max) and Hb(mass).
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Resistencia Física / Carrera / Hemoglobinas / Eritropoyetina Límite: Adult / Humans / Male Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2013 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Resistencia Física / Carrera / Hemoglobinas / Eritropoyetina Límite: Adult / Humans / Male Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2013 Tipo del documento: Article País de afiliación: Reino Unido